Discovery of [F-18]N-(2-(Diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance

Simple item page
dc.contributor.authorGreguric, Ien_AU
dc.contributor.authorTaylor, SRen_AU
dc.contributor.authorDenoyer, Den_AU
dc.contributor.authorBallantyne, Pen_AU
dc.contributor.authorBerghofer, PJen_AU
dc.contributor.authorRoselt, Pen_AU
dc.contributor.authorPham, TQen_AU
dc.contributor.authorMattner, Fen_AU
dc.contributor.authorBourdier, Ten_AU
dc.contributor.authorNeels, OCen_AU
dc.contributor.authorDorow, DSen_AU
dc.contributor.authorLoc'h, Cen_AU
dc.contributor.authorHicks, RJen_AU
dc.contributor.authorKatsifis, Aen_AU
dc.date.accessioned2010-04-06T01:05:56Zen_AU
dc.date.accessioned2010-04-30T05:08:05Zen_AU
dc.date.available2010-04-06T01:05:56Zen_AU
dc.date.available2010-04-30T05:08:05Zen_AU
dc.date.issued2009-09-10en_AU
dc.date.statistics2009-09-10en_AU
dc.description.abstractThe high melanoma uptake and rapid body clearance displayed by our series of [123I]iodonicotinamides prompted the development of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide ([18F]2), a novel radiotracer for PET melanoma imaging. Significantly, unlike fluorobenzoates, [18F]fluorine incorporation on the nicotinamide ring is one step, facile, and high yielding. [18F]2 displayed high tumor uptake, rapid body clearance via predominantly renal excretion, and is currently being evaluated in preclinical studies for progression into clinical trials to assess the responsiveness of therapeutic agents. © 2009, American Chemical Societyen_AU
dc.identifier.citationGreguric, I., Taylor, S. R., Denoyer, D., Ballantyne, P., Berghofer, P., Roselt, P., Pham, T.Q., Mattner, F., Bourdier, T., Neels, O. C., Dorow, D.S., Loc'h, C., Hicks, R. J., & Katsifis, A. (2009). Discovery of [f-18]n-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance. Journal of Medicinal Chemistry, 52(17), 5299-5302. doi:10.1021/jm9008423en_AU
dc.identifier.govdoc1520en_AU
dc.identifier.issn0022-2623en_AU
dc.identifier.issue17en_AU
dc.identifier.journaltitleJournal of Medicinal Chemistryen_AU
dc.identifier.pagination5299-5302en_AU
dc.identifier.urihttp://dx.doi.org/10.1021/jm9008423en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/3035en_AU
dc.identifier.volume52en_AU
dc.language.isoenen_AU
dc.publisherAmerican Chemical Societyen_AU
dc.subjectDrugsen_AU
dc.subjectNeoplasmsen_AU
dc.subjectRenal clearanceen_AU
dc.subjectPositron computed tomographyen_AU
dc.subjectNicotinamideen_AU
dc.subjectClinical trialsen_AU
dc.titleDiscovery of [F-18]N-(2-(Diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearanceen_AU
dc.typeJournal Articleen_AU
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal Articles